A First-in-Human Phase 1a/1b Trial to Assess the Safety Tolerability and Preliminary Efficacy of LY4170156 an Antibody-Drug Conjugate Targeting Folate Receptor a Expressing Tumor Cells in Participants with Selected Advanced Solid Tumors

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Ovarian Cancer
    Advanced Solid Tumors
  • Age: Between 18 Year(s) - 99 Year(s)
  • Gender: Female
  • Other Inclusion Criteria:
    1. Histological diagnosis of ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, NSCLC, TNBC, pancreatic cancer, or CRC
    2. For a histological diagnosis of ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, it is for patients with cancer that is resistant to prior platinum treatment (recurrence or progression within 6 months of last platinum dose)

You may not be eligible for this study if the following are true:

    1. Has a known or suspected history of active CNS involvement
    2. Has a history of carcinomatous meningitis
    3. Has a serious pre-existing medical condition(s) that, in the judgment of the Investigator, would preclude participation in this trial, including interstitial lung disease, bowel obstruction, or severe dyspnea at rest



If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.